Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion the SCORE2 randomized clinical trial

Ingrid Scott, Paul C. Van Veldhuisen, Michael S. Ip, Barbara A. Blodi, Neal L. Oden, Carl C. Awh, Derek Y. Kunimoto, Dennis M. Marcus, John J. Wroblewski, Jacqueline King

Research output: Contribution to journalArticle

67 Scopus citations

Abstract

IMPORTANCE Studies have established the efficacy and safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion. Bevacizumab is used off-label to treat this condition despite the absence of supporting data. OBJECTIVE To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretinal vein occlusion. DESIGN, SETTING, AND PARTICIPANTS The SCORE2 randomized noninferiority clinical trialwas conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab. The first participant was randomized on September 17, 2014, and the last month 6 visit occurred on May 6, 2016. Analyses included data available as of December 30, 2016. INTERVENTIONS Eyes were randomized to receive intravitreal injection of bevacizumab (1.25mg; n = 182) or aflibercept (2.0mg; n = 180) every 4 weeks through month 6. MAIN OUTCOMES AND MEASURES The primary outcomewas mean change in visual acuity (VA) letter score (VALS) from the randomization visit to the 6-month follow-up visit, based on the best-corrected electronic Early Treatment Diabetic Retinopathy Study VALS (scores range from 0-100; higher scores indicate better VA). The noninferiority margin was 5 letters, and statistical testing for noninferiority was based on a 1-sided 97.5%confidence interval. RESULTS Among 362 randomized participants (mean [SD] age, 69 [12] years; 157 [43.4%] women; mean [SD] VALS at baseline, 50.3 [15.2] [approximate Snellen VA 20/100]), 348 (96.1%) completed the month 6 follow-up visit. At month 6, the mean VALS was 69.3 (a mean increase from baseline of 18.6) in the bevacizumab group and 69.3 (a mean increase from baseline of 18.9) in the aflibercept group (model-based estimate of between-group difference,-0.14; 97.5%CI,-3.07 to ∞; P = .001 for noninferiority), meeting criteria for noninferiority. Ocular adverse events in the aflibercept group included 4 participants with intraocular pressure (IOP) more than 10mmHg greater than baseline; ocular adverse events in the bevacizumab group included 1 participant with endophthalmitis (culture negative), 9 with IOP more than 10mmHg greater than baseline, 2 with IOP higher than 35mmHg, and 1 with angle-closure glaucoma not attributed to the study drug or procedure. CONCLUSIONS AND RELEVANCE Among patients with macular edema due to central retinal or hemiretinal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual acuity after 6 months of treatment.

Original languageEnglish (US)
Pages (from-to)2072-2087
Number of pages16
JournalJAMA - Journal of the American Medical Association
Volume317
Issue number20
DOIs
StatePublished - May 23 2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this